Microbot Medical Launches Full Commercial Release of LIBERTY Robotic System Following Successful Limited Market Adoption
核心洞察
Microbot Medical (搜索) has commenced full market release of its LIBERTY Endovascular Robotic System (搜索) at the Society of Interventional Radiology (搜索) conference after successful limited market adoption by multiple healthcare systems including Emory Healthcare and Tampa General Hospital.
The LIBERTY system represents the only FDA-cleared, single-use, remotely operated robotic platform for peripheral endovascular procedures, demonstrating versatility across multiple procedure types including prostate artery embolization (搜索) and uterine fibroid embolization (搜索).
The company has expanded its commercial infrastructure from four to eight sales territories with plans to reach 12 territories by end of 2026, while recent peer-reviewed publication in the Journal of Vascular and Interventional Radiology (搜索) validates the system's clinical efficacy.
Microbot Medical (搜索) Inc. has successfully transitioned from limited to full market release of its LIBERTY Endovascular Robotic System (搜索), marking a significant milestone for the first FDA-cleared, single-use, remotely operated robotic platform for peripheral endovascular procedures. The company announced the full market release at the Society of Interventional Radiology (搜索) Annual Scientific Meeting in Toronto, following successful adoption by multiple healthcare systems during its limited market phase.
Clinical Adoption and Procedure Versatility
The LIBERTY system has been adopted by multiple healthcare systems with dozens of hospitals in their networks, including globally recognized institutions such as Emory Healthcare and Tampa General Hospital. The system has demonstrated remarkable versatility, being successfully used commercially across a variety of procedures including Prostate Artery Embolization (搜索) (PAE), Uterine Fibroid Embolization (搜索) (UFE), Genicular Artery Embolization (搜索) (GAE), Y90 mapping, Y90 deliveries, and peripheral arterial interventions.
According to Harel Gadot, Chairman, President & CEO, "It's exciting to see the level of enthusiasm among our existing customers, first when they initially use LIBERTY, utilizing it across multiple procedures, and then as they expand it to other hospital sites within their network. The variety of case types shows the system's flexibility, and its ease of use is generating high customer satisfaction."
Physicians have highlighted several key advantages of the LIBERTY system, including its precision, short learning curve, fast setup, the ability to use their preferred wires and catheters, as well as the potential to improve efficiency by reducing procedure time and number of instruments used to perform such procedures.
Scientific Validation and Peer Review
The company's commercial success has been bolstered by recent publication of its ACCESS-PVI pivotal study results in the Journal of Vascular and Interventional Radiology (搜索) (JVIR). The article, titled "In Vivo Evaluation of a Disposable Endovascular Robotic System for Arterial Peripheral Vascular Interventions: A Multicenter Feasibility Study," was authored by Dr. Francois Cornelis, a leading interventional radiologist who served as the Lead Principal Investigator for the study.
The ACCESS-PVI study was completed in 2025 and initially presented at the Society of Interventional Radiology (搜索) annual meeting in April 2025. The subsequent peer-reviewed publication represents rigorous independent validation of the study's methodology and data, considered the gold standard for clinical validation.
"We are very pleased by the publication of the ACCESS-PVI results in JVIR, a leading voice in the field. This is a recognition that speaks to the quality and impact of the study," commented Juan Diaz-Cartelle, Chief Medical Officer. "We would like to thank all the co-authors and we are looking forward to generating more clinical evidence that would foster appreciation for the benefits of the LIBERTY system."
Commercial Infrastructure Expansion
In preparation for the full market release, Microbot Medical (搜索) has significantly enhanced its commercial capabilities. The company has expanded its sales footprint from four to eight sales territories, with plans to establish 12 territories across the United States by the end of 2026. This expansion includes the addition of salespeople in key locations to support broader market penetration.
The LIBERTY system received FDA clearance in September 2025 for peripheral endovascular procedures, and the company commenced its limited market release in late 2025. The successful execution of the limited market release provided the foundation for the planned full market release at the SIR conference.
Addressing Industry Challenges
The timing of the full market release coincides with increased attention to occupational safety in interventional radiology. The Society of Interventional Radiology (搜索), along with the Cardiovascular and Interventional Radiological Society of Europe (搜索), recently adopted new guidelines published in CardioVascular and Interventional Radiology, endorsed by at least eight other medical societies. These guidelines address radiation exposure sources and musculoskeletal risks for interventional radiology staff.
This development follows a recent American Medical Association policy adopted to strengthen protections for healthcare professionals from occupational exposure to ionizing radiation. The LIBERTY system's design for precise vascular navigation while aiming to reduce radiation exposure and physical strain directly addresses these industry concerns.
Market Positioning and Future Outlook
The LIBERTY system is creating an entirely new category in the medical device market as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. Gadot noted that the level of customer adoption during the limited market release demonstrates "a shorter sales cycle compared to traditional surgical robots, which is another key differentiator and one we believe will lead to accelerated adoption."
The Society of Interventional Radiology (搜索) represents over 8,000 practicing interventional radiology physicians, trainees, medical students, scientists, and clinical associates, providing Microbot Medical (搜索) with direct access to its primary addressable U.S. target market. The company plans to showcase the LIBERTY system at booth #423 and engage directly with physicians and other stakeholders to accelerate market adoption.